The Company regularly evaluates its business and objectives to ensure that it is properly configured and sized based on changing market conditions. Accordingly, the Company has implemented certain restructuring initiatives, including consolidation of certain facilities throughout the world and rationalization of its operations. In fiscal year 2024, management initiated a restructuring plan to begin streamlining the Company's global genomics business. Management continued and primarily finalized the restructuring plan to streamline operations of the Company's global genomics business. This restructuring plan was complete by May 31, 2025.

The Company’s restructuring charges consist of severance payments, costs for outplacement services, and post-employment benefits (collectively, “employee separation costs”), other related exit costs and asset impairment charges related to restructuring activities. These amounts are partially recorded within cost of service revenues and partially recorded within general and administrative expense on the consolidated statements of operations.

Restructuring charges by segment were as follows:


	Year ended May 31,
	2025		2024
Food Safety	$	2,146	$	402
Animal Safety		7,430		1,385
Corporate		1,520		1,726
Total	$	11,096	$	3,513

Restructuring activity for the twelve months ended May 31, 2025 was as follows:


	Employee Separation Costs			Other Exit Costs			Total
Balance as of May 31, 2024	$	-		$	-		$	-
Expense		3,041			8,055			11,096
Cash Payments		(2,285	)		(481	)		(2,766	)
Asset impairments and other (1)		-			(7,574	)		(7,574	)
Balance as of May 31, 2025	$	756		$	-		$	756

(1) Asset impairment charges primarily relate to Inventory and Property and Equipment charges incurred by the Company's Animal Safety operating segment and global genomics business.